Response to "iPTH is not a significant factor influencing the tacrolimus C/D ratio"
Clin Transl Sci
.
2022 Apr;15(4):807-808.
doi: 10.1111/cts.13242.
Epub 2022 Feb 19.
Authors
Ryota Tanaka
1
,
Yosuke Suzuki
2
,
Hiroshi Watanabe
3
,
Takashi Fujioka
4
,
Kenshiro Hirata
5
,
Toshitaka Shin
6
,
Tadasuke Ando
6
,
Hiroyuki Ono
1
,
Ryosuke Tatsuta
1
,
Hiromitsu Mimata
6
,
Toru Maruyama
3
,
Hiroki Itoh
1
Affiliations
1
Department of Clinical Pharmacy, Oita University Hospital, Yufu-shi, Oita, Japan.
2
Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
3
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
4
Laboratory of Medical Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
5
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
6
Department of Urology, Faculty of Medicine, Oita University, Yufu-shi, Oita, Japan.
PMID:
35182111
PMCID:
PMC9010249
DOI:
10.1111/cts.13242
No abstract available
Publication types
Letter